News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioLineRx Ltd. Announces Cypress Bioscience Inc. (CYPB)'s and Royalty Pharma's Commitment to the Development of BL-1020 (CYP-1020) Program


1/25/2011 10:37:49 AM

JERUSALEM--(BUSINESS WIRE)--BioLineRx (TASE:BLRX) today announced that it has been advised by Royalty Pharma, the new parent company of Cypress Bioscience Inc., that it is committed to enhance the value of Cypress’ pipeline assets, which include BioLineRx’s BL-1020 (CYP-1020) compound, a novel therapeutic for schizophrenia. The clinical program for BL-1020 will be spearheaded by the Cypress development team, and together they intend to pursue the program’s continuation.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES